Literature DB >> 20422224

Bleeding risk for surgical dialysis procedures in children with hemolytic uremic syndrome.

Brent R Weil1, Sharon P Andreoli, Deborah F Billmire.   

Abstract

Children with hemolytic uremic syndrome (HUS) frequently develop acute kidney injury (AKI) requiring renal replacement therapy (RRT). Peritoneal dialysis (PD) is commonly used. Despite high rates of thrombocytopenia, there is concern that platelet transfusions may worsen HUS by exacerbating microthrombi formation. We evaluated bleeding risk for PD catheter placement with or without central venous catheter (CVC) placement in children with HUS. Records from 1998 to 2007 were searched. Data regarding patient demographics, PD catheter placement, CVC placement, occurrence of procedure-associated bleeding, and time from insertion to removal of PD catheter were collected. Patients were stratified according to those who received and those who did not receive platelet transfusions. Seventy-three patients were identified. Twenty-two (30%) patients received platelet transfusion while 51 (70%) did not. Mean preoperative platelet counts were 37,600+/-21,900/mm(3) in patients receiving transfusions and 64,800 +/- 38,800/mm(3) in patients not receiving transfusions. Sixty-seven children (92%) also underwent CVC placement. There were no bleeding complications related to these procedures in either group. No differences in time to removal of the PD catheter were detected. Although caution and sound clinical judgment must be exercised, our findings suggest that PD catheter and CVC placement can be accomplished safely in most children with HUS, without need for platelet transfusion in spite of the associated thrombocytopenia.

Entities:  

Mesh:

Year:  2010        PMID: 20422224     DOI: 10.1007/s00467-010-1530-1

Source DB:  PubMed          Journal:  Pediatr Nephrol        ISSN: 0931-041X            Impact factor:   3.714


  14 in total

Review 1.  The pathophysiology of the hemolytic uremic syndrome.

Authors:  S P Andreoli
Journal:  Curr Opin Nephrol Hypertens       Date:  1999-07       Impact factor: 2.894

2.  Hemolytic uremic syndrome: epidemiology, pathophysiology, and therapy.

Authors:  Sharon P Andreoli; Howard Trachtman; David W K Acheson; Richard L Siegler; Tom G Obrig
Journal:  Pediatr Nephrol       Date:  2002-04       Impact factor: 3.714

3.  Escherichia coli cytotoxin, haemolytic-uraemic syndrome, and haemorrhagic colitis.

Authors:  M A Karmali; M Petric; C Lim; P C Fleming; B T Steele
Journal:  Lancet       Date:  1983-12-03       Impact factor: 79.321

Review 4.  Renal transplantation in HUS patients with disorders of complement regulation.

Authors:  Lothar Bernd Zimmerhackl; Johanna Scheiring; Friederike Prüfer; C Mark Taylor; Chantal Loirat
Journal:  Pediatr Nephrol       Date:  2006-10-21       Impact factor: 3.714

5.  Practice parameter for the use of fresh-frozen plasma, cryoprecipitate, and platelets. Fresh-Frozen Plasma, Cryoprecipitate, and Platelets Administration Practice Guidelines Development Task Force of the College of American Pathologists.

Authors: 
Journal:  JAMA       Date:  1994-03-09       Impact factor: 56.272

Review 6.  Shiga-toxin-producing Escherichia coli and haemolytic uraemic syndrome.

Authors:  Phillip I Tarr; Carrie A Gordon; Wayne L Chandler
Journal:  Lancet       Date:  2005 Mar 19-25       Impact factor: 79.321

7.  Perioperative platelet transfusion: recommendations of the Agence Française de Sécurité Sanitaire des Produits de Santé (AFSSaPS) 2003.

Authors:  Charles Marc Samama; Rachid Djoudi; Thomas Lecompte; Nathalie Nathan-Denizot; Jean-François Schved
Journal:  Can J Anaesth       Date:  2005-01       Impact factor: 5.063

8.  Blood pressure in the long-term follow-up of children with hemolytic uremic syndrome.

Authors:  Laura De Petris; Alessandra Gianviti; Ugo Giordano; Armando Calzolari; Alberto E Tozzi; Gianfranco Rizzoni
Journal:  Pediatr Nephrol       Date:  2004-11       Impact factor: 3.714

9.  Long-term (15-25 years) outcome of childhood hemolytic-uremic syndrome.

Authors:  M F Gagnadoux; R Habib; M C Gubler; J L Bacri; M Broyer
Journal:  Clin Nephrol       Date:  1996-07       Impact factor: 0.975

Review 10.  Treatment and outcome of Shiga-toxin-associated hemolytic uremic syndrome (HUS).

Authors:  Johanna Scheiring; Sharon P Andreoli; Lothar Bernd Zimmerhackl
Journal:  Pediatr Nephrol       Date:  2008-08-13       Impact factor: 3.714

View more
  8 in total

Review 1.  Guidelines for the management and investigation of hemolytic uremic syndrome.

Authors:  Takashi Igarashi; Shuichi Ito; Mayumi Sako; Akihiko Saitoh; Hiroshi Hataya; Masashi Mizuguchi; Tsuneo Morishima; Kenji Ohnishi; Naohisa Kawamura; Hirotsugu Kitayama; Akira Ashida; Shinya Kaname; Hiromichi Taneichi; Julian Tang; Makoto Ohnishi
Journal:  Clin Exp Nephrol       Date:  2014-08       Impact factor: 2.801

2.  Impact of platelet transfusions in children with post-diarrheal hemolytic uremic syndrome.

Authors:  Alejandro Balestracci; Sandra Mariel Martin; Ismael Toledo; Caupolican Alvarado; Raquel Eva Wainsztein
Journal:  Pediatr Nephrol       Date:  2013-02-06       Impact factor: 3.714

Review 3.  Shiga Toxin-Associated Hemolytic Uremic Syndrome: Specificities of Adult Patients and Implications for Critical Care Management.

Authors:  Benoit Travert; Cédric Rafat; Patricia Mariani; Aurélie Cointe; Antoine Dossier; Paul Coppo; Adrien Joseph
Journal:  Toxins (Basel)       Date:  2021-04-26       Impact factor: 4.546

4.  Acute renal replacement therapy in children with diarrhea-associated hemolytic uremic syndrome: a single center 16 years of experience.

Authors:  Silviu Grisaru; Melissa A Morgunov; Susan M Samuel; Julian P Midgley; Andrew W Wade; James B Tee; Lorraine A Hamiwka
Journal:  Int J Nephrol       Date:  2011-05-26

5.  Hemolytic uremic syndrome caused by Shiga toxin-producing Escherichia coli in children: incidence, risk factors, and clinical outcome.

Authors:  Elisa Ylinen; Saara Salmenlinna; Jani Halkilahti; Timo Jahnukainen; Linda Korhonen; Tiia Virkkala; Ruska Rimhanen-Finne; Matti Nuutinen; Janne Kataja; Pekka Arikoski; Laura Linkosalo; Xiangning Bai; Andreas Matussek; Hannu Jalanko; Harri Saxén
Journal:  Pediatr Nephrol       Date:  2020-04-22       Impact factor: 3.714

6.  Acute peritoneal dialysis, complications and outcomes in 389 children with STEC-HUS: a multicenter experience.

Authors:  Paula A Coccia; Flavia B Ramírez; Angela D C Suárez; Laura F Alconcher; Alejandro Balestracci; Laura A García Chervo; Iliana Principi; Aída Vázquez; Viviana M Ratto; María Celia Planells; Jorge Montero; Mariana Saurit; Maria Graciela Pérez Y Gutiérrez; María Celeste Puga; Elsa M Isern; María Carolina Bettendorff; Marcela V Boscardin; Marta Bazán; Mario A Polischuk; Alejo De Sarrasqueta; Adriana Aralde; Diego B Ripeau; Daniela C Leroy; Nahir E Quijada; Romina S Escalante; Marta I Giordano; Cristian Sánchez; Verónica S Selva; Alejandra Caminiti; José María Ojeda; Pablo Bonany; Sandra E Morales; Daniel Allende; María Andrea Arias; Andrea M Exeni; Jésica D Geuna; Larisa Arrúa
Journal:  Pediatr Nephrol       Date:  2021-01-04       Impact factor: 3.714

7.  Recombinant Human Erythropoietin Therapy for a Jehovah's Witness Child With Severe Anemia due to Hemolytic-Uremic Syndrome.

Authors:  Da Eun Woo; Jae Min Lee; Yu Kyung Kim; Yong Hoon Park
Journal:  Korean J Pediatr       Date:  2016-02-29

Review 8.  Shiga Toxin-Associated Hemolytic Uremic Syndrome: A Narrative Review.

Authors:  Adrien Joseph; Aurélie Cointe; Patricia Mariani Kurkdjian; Cédric Rafat; Alexandre Hertig
Journal:  Toxins (Basel)       Date:  2020-01-21       Impact factor: 4.546

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.